Search filters

Authors whose works are in public domain in at least one jurisdiction

List of works by Daniel J Coleman

BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer

scientific article published on 17 April 2019

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.

scientific article published on 03 June 2016

Coibamide A, a natural lariat depsipeptide, inhibits VEGFA/VEGFR2 expression and suppresses tumor growth in glioblastoma xenografts.

scientific article

Endothelin-1 is a transcriptional target of p53 in epidermal keratinocytes and regulates ultraviolet-induced melanocyte homeostasis.

scientific article published on 24 January 2013

Grp1-associated scaffold protein regulates skin homeostasis after ultraviolet irradiation.

scientific article

IL-1 Receptor-Knockout Mice Develop Epidermal Cysts and Show an Altered Innate Immune Response after Exposure to UVB Radiation

scientific article

Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer.

scientific article published on 20 November 2017

LSD1 activates a lethal prostate cancer gene network independently of its demethylase function.

scientific article published on 26 March 2018

Loss of keratinocytic RXRα combined with activated CDK4 or oncogenic NRAS generates UVB-induced melanomas via loss of p53 and PTEN in the tumor microenvironment.

scientific article

Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer

scientific article published on 07 March 2019

RXRα ablation in epidermal keratinocytes enhances UVR-induced DNA damage, apoptosis, and proliferation of keratinocytes and melanocytes.

scientific article

Retinoid-X-receptors (α/β) in melanocytes modulate innate immune responses and differentially regulate cell survival following UV irradiation

scientific article (publication date: May 2014)